TG Therapeutics - TGTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.00
  • Forecasted Upside: 105.25 %
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$8.77
▲ +0.75 (9.35%)

This chart shows the closing price for TGTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TG Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TGTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TGTX

Analyst Price Target is $18.00
▲ +105.25% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for TG Therapeutics in the last 3 months. The average price target is $18.00, with a high forecast of $19.00 and a low forecast of $17.00. The average price target represents a 105.25% upside from the last price of $8.77.

This chart shows the closing price for TGTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in TG Therapeutics. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/12/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
9/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/9/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/9/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 2 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 2 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 2 sell ratings
11/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/13/2022B. RileyLower TargetBuy$23.00 ➝ $17.00Low
5/20/2022Bank of AmericaInitiated CoverageUnderperformHigh
5/9/2022Cantor FitzgeraldReiterated RatingOverweightHigh
4/19/2022B. RileyLower TargetBuy$35.00 ➝ $23.00High
4/18/2022HC WainwrightLower TargetBuy$68.00 ➝ $19.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
2/23/2022B. RileyLower TargetBuy$49.00 ➝ $35.00High
1/24/2022HC WainwrightLower TargetBuy$75.00 ➝ $70.00High
12/1/2021Evercore ISILower TargetOutperform$55.00 ➝ $36.00Low
12/1/2021HC WainwrightLower TargetBuy$84.00 ➝ $75.00High
12/1/2021The Goldman Sachs GroupLower TargetSell$26.00 ➝ $13.00High
11/15/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$33.00 ➝ $26.00High
11/7/2021Evercore ISIReiterated RatingBuyMedium
8/2/2021HC WainwrightLower TargetBuy$89.00 ➝ $84.00High
4/20/2021The Goldman Sachs GroupInitiated CoverageNeutral$50.00High
4/19/2021HC WainwrightBoost TargetBuy$79.00 ➝ $89.00High
2/8/2021HC WainwrightBoost TargetBuy$78.00 ➝ $79.00Medium
2/5/2021B. RileyBoost TargetBuy$90.00 ➝ $95.00High
1/19/2021HC WainwrightBoost TargetBuy$61.00 ➝ $78.00Low
12/10/2020HC WainwrightBoost TargetBuy$38.00 ➝ $61.00High
10/28/2020Cantor FitzgeraldBoost TargetOverweight$30.00 ➝ $48.00Low
9/1/2020JPMorgan Chase & Co.Initiated CoverageOverweight$38.00High
8/11/2020HC WainwrightBoost TargetBuy$32.00 ➝ $38.00Medium
8/10/2020B. RileyReiterated RatingBuy$37.00Medium
6/15/2020B. RileyReiterated RatingBuy$37.00Low
6/5/2020Evercore ISIInitiated CoverageOutperform$60.00High
6/1/2020B. RileyReiterated RatingBuy$37.00High
5/29/2020HC WainwrightReiterated RatingBuyHigh
5/18/2020HC WainwrightReiterated RatingBuy$32.00Medium
5/17/2020B. RileyBoost TargetBuy$29.00 ➝ $37.00Medium
5/12/2020HC WainwrightReiterated RatingBuy$32.00Medium
5/6/2020Cantor FitzgeraldBoost TargetOverweight$19.00 ➝ $35.00High
5/6/2020B. RileyBoost TargetBuy$25.00 ➝ $29.00High
5/5/2020HC WainwrightBoost TargetBuy$24.00 ➝ $32.00High
4/17/2020B. RileyReiterated RatingBuy$25.00High
1/17/2020HC WainwrightBoost TargetBuy$20.00 ➝ $24.00High
12/10/2019HC WainwrightReiterated RatingBuy$20.00High
11/27/2019B. RileyInitiated CoverageBuy$12.00High
11/12/2019HC WainwrightReiterated RatingBuy$20.00Medium
10/28/2019HC WainwrightReiterated RatingBuy$20.00Medium
6/11/2019B. RileyReiterated RatingBuyMedium
5/13/2019Cantor FitzgeraldReiterated RatingBuy$17.00High
4/12/2019HC WainwrightReiterated RatingBuy$20.00Low
3/29/2019Cantor FitzgeraldInitiated CoverageOverweight$17.00High
2/6/2019Jefferies Financial GroupReiterated RatingBuy$8.00High
1/22/2019HC WainwrightReiterated RatingBuyHigh
1/8/2019B. RileyInitiated CoverageBuy$10.00Low
11/12/2018HC WainwrightReiterated RatingBuy$20.00High
11/2/2018HC WainwrightReiterated RatingBuy$21.00Medium
9/26/2018LADENBURG THALM/SH SHSet TargetBuy$27.00N/A
9/25/2018Raymond JamesDowngradeStrong-Buy ➝ Outperform$22.00 ➝ $12.00High
8/7/2018HC WainwrightReiterated RatingBuy$38.00High
4/25/2018Raymond JamesReiterated RatingBuyLow
4/19/2018Raymond JamesReiterated RatingBuyLow
3/9/2018B. RileyReiterated RatingBuy ➝ Buy$21.50 ➝ $27.00Medium
1/17/2018B. RileyReiterated RatingBuy$21.50Low
1/16/2018HC WainwrightReiterated RatingBuy$33.00Low
1/8/2018HC WainwrightReiterated RatingBuy$33.00Low
12/12/2017Raymond JamesReiterated RatingBuyLow
12/11/2017HC WainwrightReiterated RatingBuy$33.00High
12/11/2017B. RileyReiterated RatingBuy$21.50High
(Data available from 12/4/2017 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
5/8/2022
  • 1 very positive mentions
  • 15 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
6/7/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/7/2022
  • 2 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/6/2022
  • 5 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/5/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
10/5/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/4/2022
  • 5 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/4/2022

Current Sentiment

  • 5 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
TG Therapeutics logo
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Read More

Today's Range

Now: $8.77
Low: $7.65
High: $8.83

50 Day Range

MA: $6.62
Low: $5.01
High: $9.34

52 Week Range

Now: $8.77
Low: $3.48
High: $20.69

Volume

3,452,508 shs

Average Volume

2,983,783 shs

Market Capitalization

$1.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.23

Frequently Asked Questions

What sell-side analysts currently cover shares of TG Therapeutics?

The following Wall Street sell-side analysts have issued reports on TG Therapeutics in the last year: B. Riley, Bank of America Co., Cantor Fitzgerald, HC Wainwright, and StockNews.com.
View the latest analyst ratings for TGTX.

What is the current price target for TG Therapeutics?

2 Wall Street analysts have set twelve-month price targets for TG Therapeutics in the last year. Their average twelve-month price target is $18.00, suggesting a possible upside of 105.2%. HC Wainwright has the highest price target set, predicting TGTX will reach $19.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $17.00 for TG Therapeutics in the next year.
View the latest price targets for TGTX.

What is the current consensus analyst rating for TG Therapeutics?

TG Therapeutics currently has 1 sell rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TGTX will outperform the market and that investors should add to their positions of TG Therapeutics.
View the latest ratings for TGTX.

What other companies compete with TG Therapeutics?

How do I contact TG Therapeutics' investor relations team?

TG Therapeutics' physical mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company's listed phone number is (212) 554-4484 and its investor relations email address is [email protected] The official website for TG Therapeutics is www.tgtherapeutics.com. Learn More about contacing TG Therapeutics investor relations.